Tanezumab
Cancer Pain
Pfizermonoclonal_antibodyPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Cancer Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Oxycodone Deventer Ziekenhuis | Phase 4 | BB |
LIDOCAINE Instituto Nacional de Cancer, Brazil | Phase 2/3 | BB |
LIDOCAINE National and Kapodistrian University of Athens | Phase 2/3 | BB |
ETHYLICUM Sindh Institute of Urology and Transplantation | Phase 4 | BB |
NEPENTHE Instituto Nacional de Cancer, Brazil | Phase 3 | BB |
View all 21 →
Same molecule, other indications
Tanezumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →